Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H2 2017, provides an overview of the Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline landscape.

HIV is a virus which attacks the immune system, and weakens ability to fight infections and disease. Symptoms include fever, sore throat, body rash, joint pain, muscle pain and swollen glands. The most common ways HIV is spread are by having vaginal or anal intercourse without a condom with someone who has HIV/AIDS, sharing needles or syringes with someone who has HIV/AIDS, being deeply punctured with a needle or surgical instrument contaminated with HIV and getting HIV-infected blood, semen, or vaginal secretions into open wounds or sores.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Human Immunodeficiency Virus (HIV) Infections (AIDS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 1, 15, 46, 42, 1, 4, 104, 66 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 16, 20, 55 and 62 molecules, respectively.

Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

AbbVie Inc
Abivax SA
AdAlta Ltd
Advanced Genetic Systems Inc
Akshaya Bio Inc
Altor BioScience Corp
Altravax Inc
Amarna Therapeutics BV
American Gene Technologies International Inc
Amunix Operating Inc
Antigen Express Inc
Aphios Corp
Apotex Inc
Argos Therapeutics Inc
B Cell Design SAS
Biological Mimetics Inc
Bionor Pharma AS
Biotron Ltd
Bolder Biotechnology Inc
Bristol-Myers Squibb Co
Bukwang Pharm Co Ltd
Cadila Healthcare Ltd
Calimmune Inc
CEL-SCI Corp
Celgene Corp
Celldex Therapeutics Inc
Chipscreen Biosciences Ltd
Cocrystal Pharma Inc
CompleGen Inc
Consegna Pharma Inc
ContraVir Pharmaceuticals Inc
Critical Outcome Technologies Inc
Curevac AG
Cytodyn Inc
Enzo Biochem Inc
eTheRNA Immunotherapies NV
Etubics Corp
Excision BioTherapeutics Inc
FIT Biotech Oy
Fountain Biopharma Inc
Frontier Biotechnologies Inc
Galmed Pharmaceuticals Ltd
GeneCure LLC
Genetic Immunity Inc
GeoVax Labs Inc
Gilead Sciences Inc
GlaxoSmithKline Plc
Globeimmune Inc
GW Pharmaceuticals Plc
Hanmi Pharmaceuticals Co Ltd
Heat Biologics Inc
iCo Therapeutics Inc.
ID Pharma Co Ltd
IGXBio Inc
Immune Response BioPharma Inc
ImmunoClin Corp
Immunocore Ltd
Immunotope Inc
Immusoft Corp
ImQuest Life Sciences Inc
InnaVirVax SA
Innovative Targeting Solutions Inc
Inovio Pharmaceuticals Inc
Japan Tobacco Inc
Johnson & Johnson
Kainos Medicine Inc
Karyopharm Therapeutics Inc
KPI Therapeutics Inc
Kymab Ltd
Longevity Biotech Inc
MacroGenics Inc
Medivir AB
Merck & Co Inc
Moderna Therapeutics Inc
Mologen AG
Mycenax Biotech Inc
Mymetics Corp
Myrexis Inc
NanoViricides Inc
Navigen Inc
NeED Pharma srl
New World Laboratories Inc
Novartis AG
Omeros Corp
Oncolys BioPharma Inc
Oncovir Inc
Orbis Biosciences Inc
Osel Inc
OyaGen Inc
PaxVax Inc
Peregrine Pharmaceuticals Inc
Pharis Biotec GmbH
Phoenix Biotechnology Inc
PlantForm Corp
Profectus BioSciences Inc
Recombio SL
Relmada Therapeutics Inc
Rodos BioTarget GmbH
Samjin Pharm Co Ltd
Sangamo Therapeutics Inc
Sanofi
Sanofi Pasteur SA
Spider Biotech
Spring Bank Pharmaceuticals Inc
ST Pharm Co., Ltd.
Starpharma Holdings Ltd
Susavion Biosciences Inc
Taiga Biotechnologies Inc
TaiMed Biologics Inc
Takara Bio Inc
Takeda Pharmaceutical Co Ltd
TechnoVax Inc
TeneoBio Inc
Theratechnologies Inc
Theravectys SA
Transgene Biotek Ltd
TVAX Biomedical Inc
United Biomedical Inc
Vaccibody AS
Vault Pharma Inc
VG Life Sciences Inc
Vichem Chemie Research Ltd
ViiV Healthcare UK Ltd
Viriom Inc
ViroStatics srl
XL-protein GmbH